N-Glycolyl GM3 cancer vaccine

Drug Profile

N-Glycolyl GM3 cancer vaccine

Alternative Names: CIMAVaxG vaccine; N-glicolil GM3/VSSP; N-Glycolyl GM3/Vssp vaccine; N-glycolyl therapeutic vaccine; N-GlycolylGM3/VSSP/Montanide-ISA-51-vaccine; NGcGM3/VSSP vaccine

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Center of Molecular Immunology
  • Developer Center of Molecular Immunology; Recombio
  • Class AIDS vaccines; Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Breast cancer
  • Phase II Malignant melanoma

Most Recent Events

  • 09 Jan 2017 Center of Molecular Immunology plans a phase I/II trial in Small cell lung cancer in Cuba (RPCEC00000224)
  • 16 Dec 2016 Center of Molecular Immunology plans a phase II/III trial in Breast cancer (Combination therapy, First-line therapy, Metastatic disease) in Cuba (SC) (RPCEC00000220)
  • 14 Oct 2016 The Center of Molecular Immunology plans a phase-I/II clinical trial in Breast cancer (Combination therapy, First-line therapy, Metastatic disease) in Cuba (SC) (RPCEC00000218)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top